Significant advancements have been made in the mitigation of tumor hypoxia through the administration of oxygen to tumors utilizing various oxygen carriers, including Hb oxygen carriers, non-Hb oxygen carriers, and hybrid proteins, among others (Luo et al., 2018; Wang H. et al., 2020). The gene discussed is GSTM1; the disease is neoplasm.